Muc4/sialomucin complex (SMC) is a multifunctional glycoprotein complex which can repress apoptosis in transfected tumor cells. Its transmembrane subunit acts as an intramembrane ligand for the receptor tyrosine kinase ErbB2 to induce the phosphorylation of ErbB2 and, by acting synergistically with the ErbB3 ligand neuregulin, can potentiate the phosphorylation of ErbB2 and ErbB3. In the present study we show that Muc4/ SMC alone robustly induces the phosphorylation of ErbB2 to enhance the tyrosine phosphate epitope (Tyr1248) recognized by anti-phospho-ErbB2. Although this tyrosine phosphorylation has been implicated in cell transformation, it does not activate any of the three mitogen-activated protein kinases (MAPKs) or protein kinase B/Akt of the phosphatidyl inositol 3-kinase pathway. Instead, Muc4/SMC expression induces upregulation of the cell cycle inhibitor p27 kip , consistent with the expression of Muc4/SMC in differentiated, rather than proliferative, epithelial cells. Interestingly, a combination of Muc4/SMC and neuregulin downregulate p27 kip and activate protein kinase B/Akt. These observations suggest that Muc4/SMC acts as a regulator of differentiation by inducing a limited phosphorylation of ErbB2 and a modulator of proliferation when acting synergistically with neuregulin to induce a more extensive phosphorylation on both ErbB2 and ErbB3.
Introduction
The ErbB family of transmembrane receptor tyrosine kinases (ErbB1/epidermal growth factor receptor, ErbB2, ErbB3, ErbB4) has been implicated in both differentiation and neoplasia (Alroy and Yarden, 1997) . Thus, there is considerable interest in the signaling pathways derived from these receptors in order to understand such apparently schizophrenic behaviors (Carraway and Sweeney, 2001) . In many physiological contexts signaling through the ErbBs is induced by the formation of ErbB heterodimers, whose cytoplasmic tails are phosphorylated and coupled to SH2-containing proteins to initiate cellular signaling pathways Riese and Stern, 1998; Olayioye et al., 1998) . The type of heterodimer formed is dependent on the receptor ligand involved and thus determines the nature of the signaling pathway specified (Klapper et al., 2000) . In many instances the preferred heterodimization partner is ErbB2. Since no soluble ligand has been described for ErbB2, it is often considered to be only a coreceptor, rather than a receptor, in the ErbB signaling complexes (Klapper et al., 2000) . However, this view is too simplistic, since we have described a transmembrane glycoprotein Muc4/sialomucin complex (SMC), which can form a ligand-receptor type of intramembrane complex with ErbB2 and modulate its phosphorylation .
Muc4/SMC is itself a heterodimeric glycoprotein (Sherblom and Carraway, 1980) composed of a mucin subunit ASGP-1 (ascites sialoglycoprotein) (Carraway and Spielman, 1986 ) and a transmembrane subunit ASGP-2 encoded by a single gene (Sheng et al., 1992; Wu et al., 1994) and translated into a single precursor polypeptide which is cleaved intracellularly to yield the two subunits . ASGP-2 contains two epidermal growth factor (EGF) domains with the conserved amino acid residues of active EGF-like growth factors (Sheng et al., 1992) , one of which acts as a ligand for ErbB2 . Muc4/SMC was originally isolated from a highly malignant rat mammary adenocarcinoma (Sher-blom and Carraway, 1980) and shown to be present in the membranes of these cells, at least in part as a complex with ErbB2 . Moreover, Muc4/SMC has been shown to be present with ErbB2 in highly aggressive human breast cancers . In contrast, Muc4/SMC is also expressed in many normal epithelia (Carraway et al., 2002) , including those of the airway (McNeer et al., 1998b) , ocular surface (Price-Schiavi et al., 1998; Pflugfelder et al., 2000) , female reproductive tract (McNeer et al., 1998a; Idris and Carraway, 1999) , lacrimal gland , mammary gland (Rossi et al., 1996) and oral cavity . All of these tissues also express ErbB2, and Muc4/SMCErbB2 complexes have been demonstrated in these epithelia in every case examined Arango et al., 2001; Idris et al., 2001) .
These results suggest that Muc4/SMC may be an important modulator of ErbB2 and of ErbB signaling in epithelia and in tumors, and that it may contribute to that schizophrenic behavior of the ErbB signaling. A clue to the signaling capabilities of Muc4/SMC was ascertained from studies of the effects of Muc4/SMC on ErbB2 phosphorylation . Tetracycline-regulated Muc4/SMC transfectants of A375 melanoma cells were treated with or without neuregulin in the present or absence of tetracycline to control expression of Muc4/SMC. Muc4/SMC expression in the absence of neuregulin induces a modest tyrosine phosphorylation of ErbB2, but not of the neuregulin receptor ErbB3. Neuregulin treatment without Muc4/SMC expression causes a greater phosphorylation of ErbB2 and similar phosphorylation of ErbB3. Most importantly, combined neuregulin treatment and Muc4/SMC expression cause a synergistic increase in the phosphorylation of both ErbB2 and ErbB3. Finally, expression of Muc4/SMC was demonstrated to repress apoptosis in these cells with or without neuregulin treatment . In contrast, Muc4/SMC expression had an effect on cell proliferation only in the presence of neuregulin .
To develop a better understanding of the role of Muc4/SMC in signaling, we have examined its effects on the specificity of ErbB phosphorylation and on pathways implicated in ErbB regulation of apoptosis. Muc4/SMC robustly activates the phosphorylation of ErbB2 tyrosine 1248 recognized by a specific antiphospho-ErbB2 (DiGiovanna and Stern, 1995) . Although this tyrosine residue has been implicated in cell transformation (Ben-Levy et al., 1994) , Muc4/SMC expression alone does not activate the primary pathways of transformation, Erk and PI 3-kinase. However, these pathways are activated by a combination of neuregulin and Muc4/SMC. Finally, Muc4/SMC enhances the expression of the cell cycle inhibitor p27 kip , which has been implicated in differentiation and apoptosis (Sgambato et al., 2000) . Most interestingly, this effect can be overridden by adding neuregulin. These results, plus our studies on the localization of Muc4/SMC in epithelia, suggest a model by which Muc4/SMC can play a role in epithelial differentiation and as a potential sensor of epithelial damage.
Results
Tyrosine phosphorylation of ErbB2 is up-regulated in insect cells by co-expression of ASGP-2
The insect cell expression system has been a useful tool to study molecular interactions of ErbB receptors and their ligands because it does not produce these receptors Sliwkowski et al., 1994) , thus eliminating complications in the interpretations of experiments. In the previous studies, we used this system to demonstrate the specific interaction of ErbB2 and the transmembrane subunit of Muc4, ASGP-2 . Here, in order to examine the effect of this interaction on the tyrosine kinase activity of ErbB2, ErbB2 was expressed in insect cells with or without coexpression of ASGP-2. Immunoprecipitated ErbB2 from these infected cells was blotted with anti-ErbB2 and antiphosphotyrosine antibodies. In this analysis, tyrosine phosphorylation of ErbB2 was clearly up-regulated by co-expression of ASGP-2 (Figure 1 ), suggesting that the interaction of the two molecules results in the enhanced tyrosine kinase activity of ErbB2. Notably, unlike activation by other known ligands for ErbB receptors, ASGP-2 did not interact with or induce phosphorylation of (data not shown) the other ErbB receptors when co-expressed in insect cells. It is important to note that activation of ErbB2 by other known EGF-like ligands requires heterodimeric complex formation of ErbB2 and other members of the ErbB receptor family Yarden and Sliwkowski, 2001) . In contrast, our data indicate that ErbB2 activation by ASGP-2 does not require heterodimeric complex formation, and that ASGP-2 can directly activate ErbB2 in the absence of other receptors. These observations strongly suggest a novel feature of ASGP-2 which can directly regulate ErbB2 activity. Muc4/SMC up-regulation leads to phosphorylation of ErbB-2 at tyrosine 1248 residue in A375 tumor Previously, we used a human melanoma xenograft model to show the effect of Muc4/SMC up-regulation on tumor progression and metastasis. In this model, A375 cells transfected for tetracycline inducible expression of Muc4/SMC (Tet-Off system) were inoculated into nude mice, and Muc4/SMC expression was regulated in vivo by oral administration of tetracycline (Komatsu et al., 2000 . These studies revealed that Muc4/SMC up-regulation leads to suppression of tumor apoptosis, rapid tumor growth, and distant metastasis in recipient animals. In order to test the hypothesis that the observed tumor promoting effects of Muc4/SMC are mediated by its ability to modulate ErbB-2/HER2 activity, we examined the transplanted tumor in situ for changes in the level of ErbB2 tyrosine phosphorylation before and after the in vivo induction of Muc4/SMC expression. For this purpose, we used a set of the two anti-ErbB2 antibodies that can distinctly recognize either tyrosine phosphorylated or nonphosphorylated epitope within the C-terminal region of ErbB2 (aa 1242 -1255). Thus, anti-phospho ErbB2 monoclonal antibody (Neomarkers Ab-18) recognizes specifically the ErbB2 molecule phosphorylated at tyrosine 1248 (Tyr1248). Anti-ErbB-2 antibody Ab-17 recognizes the same site with a non-phosphorylated epitope. Tyr1248 is one of the known auto-phosphorylation/effector binding sites of the ErbB2 cytoplasmic tail (Akiyama et al., 1991) . This phosphotyrosine has been shown to be a site for Shc binding (Ricci et al., 1995) and for potentiating cellular transformation (Akiyama et al., 1991) .
To determine the effect of Muc4/SMC up-regulation on the Tyr1248 phosphorylation of ErbB2 endogenously expressed in the xenograft A375 tumor, tumor sections were immunostained with Ab-18 and Ab-17 antibodies. Muc4-Off tumor was stained only weakly with Ab-18, indicating that few ErbB2 molecules in these cells are phosphorylated at Tyr1248 when Muc4/ SMC expression is repressed (Figure 2 ). Muc4/SMC up-regulation, however, dramatically increased Ab-18 staining, indicating a significant increase in the phosphorylation of this tyrosine residue (Figure 2 ). Conversely, Muc4/SMC up-regulation substantially diminished the staining of the tumors by Ab-17 antibody, which recognizes the nonphosphorylated peptide, further demonstrating that most of the ErbB2 molecules in these tumor cells have been phosphorylated when Muc4/SMC expression is induced. Association of Muc4/SMC and ErbB2 was detected in tumor lysates by co-immunoprecipitation analyses as demonstrated previously in cultured cells (data not shown). In the control experiments using the A375 cells transfected with a Tet repressor/transactivator gene and an empty expression vector , the pattern of tumor staining did not change due to the tetracycline administration to the recipient animals (data not shown). In total, these observations clearly demonstrated that Muc4/SMC overexpression leads to extensive ErbB2 phosphorylation at Tyr1248 in A375 tumor.
Muc4/SMC up-regulation leads to Tyr1248 phosphorylation in both suspension and adherent cells in culture
To determine whether the observed effect of Muc4/ SMC on ErbB2 phosphorylation is independent of the growth conditions or host-tumor interactions, we examined the Tyr1248 phosphorylation of ErbB2 in cultured A375 cells using the same set of anti-ErbB2 antibodies. Immunofluorescence analyses demonstrated that the removal of tetracycline followed by Muc4/ SMC induction results in phosphorylation of tyrosine 1248, just as observed in vivo (Figure 3 ). In culture, most of the A375 cells lose cell adhesion upon overexpression of Muc4/SMC due to the steric effect of large mucin molecule (Komatsu et al., 1997) , whereas some cells remain attached. Importantly, Tyr1248 phosphorylation of ErbB2 was observed regardless of adhesion state of the cells, indicating that this effect is mediated by a mechanism independent from adhesion-regulated signaling events. In the control A375 transfectants in which Muc4/SMC is not expressed, the pattern of anti-ErbB2 immunostaining did not change after the removal of tetracycline (data not shown), demonstrating that the observed effect on tyrosine phosphorylation is caused by up- regulation of Muc4/SMC. The effect of Muc4/SMC on ErbB2 phosphorylation was further confirmed by Western blot analyses of A375 cell lysates using another anti-phospho-ErbB2 antibody (Upstate Biotechnology) which also specifically recognizes the ErbB2 phosphorylated at Tyr1248 (Figure 4 ). The expression level of ErbB2 did not change upon Muc4/ SMC induction, but staining of ErbB2 by the antiphospho-ErbB2 was induced. Based on these observations, we conclude that Muc4/SMC promotes ErbB2 phosphorylation at tyrosine 1248 via an intracellular signaling mechanism, presumably by up-regulating the tyrosine kinase activity of ErbB2. Given that Muc4/ SMC can interact specifically with ErbB2 through its EGF-like domain, these studies provide further supporting evidence that Muc4/SMC is an intramembrane ligand for HER2/ErbB-2 that can modulate its receptor tyrosine kinase activity. No changes in any of the three MAP kinase phosphorylations were observed that could be related to the changes in apoptosis that occur in these cells, as described in Table 1 . Thus, the MAP kinase pathways do not appear to be involved in the direct effect of Muc4/SMC on ErbB2 signaling and repression of apoptosis. Our previous studies showed that Muc4/SMC could potentiate the phosphorylation of both ErbB2 and ErbB3 ) (see Table 1 ). Moreover, the ErbB2/ErbB3 heterodimer can be a potent activator of the phosphoinositol 3-kinase (PI3K) pathway and its downstream effector protein kinase B/Akt (Franke et al., 1997) . Protein kinase B/Akt is recognized as an important repressor of apoptosis (Franke et al., 1997) . To determine whether protein kinase B/Akt is involved in the suppression of apoptosis by Muc4/SMC, we measured protein kinase B/Akt activities in Muc4/SMC-expressing and -nonexpressing cells. As shown in Figure 5 , the expression of Muc4/SMC failed to change the protein kinase B/ Akt activity in the A375 cells. Similarly, inhibitors of PI3K failed to block the suppression of apoptosis by expression of Muc4/SMC (data not shown). In contrast, treatment of the A375 cells with neuregulin did cause an increase in protein kinase B/Akt activity, which was substantially potentiated by the expression of Muc4/SMC in the A375 cells ( Figure 5 ). These results suggest that Muc4/SMC can modulate downstream pathways influencing apoptosis by two separate mechanisms. The first of these requires only the expression of Muc4/SMC. The second requires neuregulin and acts via PI3K and protein kinase B/Akt, a common mechanism for blocking apoptosis (Franke et al., 1997) . In this second pathway Muc4/SMC acts as a potentiator of the stimulation of the pathway by the growth factor neuregulin. These effects are consistent with our previous observations that Muc4/SMC potentiates the neuregulin-induced phosphorylation of ErbB3 ) (see Table 1 ).
Effects of

Muc4/SMC expression up-regulates p27 kip expression
Recent studies have suggested that Muc4/SMC might be involved in epithelial cell differentiation as well as apoptosis. In particular, Muc4/SMC is expressed in only the most superficial cell layers of stratified epithelia of the ocular surface (Price-Schiavi et al., 1998b; Pflugfelder et al., 2000) , female reproductive tract (Idris and Carraway, 1999) and oral cavity , those cells which are in the highest state of differentiation. One key component implicated in both apoptosis and differentiation is the cell cycle inhibitor p27 kip (Sgambato et al., 2000) . To determine whether Muc4/SMC expression affects p27 kip levels, we performed immunoblots with anti-p27 kip on cells expressing and not expressing Muc4/SMC. As shown in Figure 6 , expression of Muc4/SMC resulted in the up-regulation of p27 kip . Activation of protein kinase B/ Akt has previously been reported to down-regulate Figure 5 Western blot analysis of protein kinase B/Akt phosphorylation in Muc4/SMC-expressing and -non-expressing cells treated with or without neuregulin. A375 cells with Muc4/SMC ON or OFF were treated with 0 -1 nM neuregulin, as described previously . Cell lysates were immunoblotted with antibodies recognizing phospho-Akt or Akt protein.
Nrg, neuregulin. Data are representative of three separate experiments Figure 6 Western blot analysis of p27 kip expression in Muc4/ SMC-expressing and -non-expressing cells under apoptotic and non-apoptotic conditions. A375 cells with Muc4/SMC ON and OFF were treated under conditions which induce (BSA) or do not induce apoptosis (FCS), as described previously . Cell lysates were immunoblotted with antibodies recognizing p27 . Since protein kinase B/Akt activation is potentiated by neuregulin in the presence of Muc4/ SMC, we tested the effects of this combination on the expression of p27 kip in the A375 cells. As shown in Figure 7 , neuregulin is able to reverse the up-regulation of p27 kip by Muc4/SMC. These results support our hypothesis that Muc4/SMC can act as a modulator of cell behavior through its activation of ErbB2 and its signaling complexes and pathways.
Discussion
Muc4/SMC is a heterodimeric glycoprotein complex composed of a mucin subunit and a transmembrane subunit, the latter of which acts as an intramembrane ligand for the class I growth factor receptor ErbB2 . Transfection studies with A375 melanoma cells indicate that Muc4/SMC is multifunctional, blocking cell -cell and cell -matrix adhesions (Komatsu et al., 1997) , reducing susceptibility to killer cells , promoting tumor cell metastasis (Komatsu et al., 2000) , promoting tumor growth ) and repressing apoptosis . Since the anti-adhesive effects of the mucin subunit ASGP-1 are expected to enhance apoptosis, we have proposed that the anti-apoptotic effects of Muc4/SMC are due to its activation of ErbB2 and subsequent downstream signaling events.
Previously, we have shown that Muc4/SMC alone can induce phosphorylation of ErbB2 . In the presence of neuregulin Muc4/SMC acts synergistically to enhance phosphorylations of both ErbB2 and ErbB3. By using a specific anti-phosphoErbB2 and the antibody which recognizes its unphosphorylated peptide, we have now shown an essentially quantitative phosphorylation of the tyrosine residue recognized by this antibody (Tyr1248 of ErbB2). Thus, the additional phosphorylations triggered by the combination of neuregulin and Muc4/SMC must involve other tyrosines of the ErbB2.
Tyr1248 has been implicated in cell transformation (Akiyama et al., 1991) . However, phosphorylation of Tyr1248 induced by Muc4/SMC alone does not activate any of the three MAP kinases or protein kinase B/Akt kinase associated with downstream signaling from ErbBs. Instead, Muc4/SMC is able to potentiate activation of the protein kinase B/Akt triggered by neuregulin. In this regard Muc4/SMC acts as a modulator of signaling through neuregulin, as described earlier , enhancing the neuregulin effect to potentiate both cell proliferation and apoptosis, both of which may be affected by protein kinase B/Akt.
The synergism with neuregulin does not explain the effect of Muc4/SMC alone. A clue to that mechanism is offered by the ability of Muc4/SMC alone to enhance the expression of p27 kip , a cell cycle regulator shown to modulate apoptosis (Sgambato et al., 2000) . Importantly, the combined effects of Muc4/SMC and neuregulin cause a down-regulation of p27 kip . Thus, Muc4/SMC appears to have the ability to function as a modulator of this important cellular regulator. Given our knowledge of Muc4/SMC associations with epithelia, a link between Muc4/SMC and p27 kip is not surprising. Muc4/SMC in epithelia is associated with differentiated tissues. In mammary gland Muc4/ SMC is increased in alveoli during mid-pregnancy as the cells are differentiating to become secretory (PriceSchiavi et al., 1998a) . Similarly, Muc4/SMC is associated with differentiated cells in simple epithelia of the intestine (Rossi et al., 1996) , female reproductive tract (Idris and Carraway, 1999) and lacrimal gland . Perhaps most telling is the expression of Muc4/SMC in stratified epithelia. In all of those we have examined, including the cornea (Price-Schiavi et al., 1998b), conjuctiva (Price-Schiavi et al., 1998b), cervix (Idris and Carraway, 1999) , vagina (Idris and Carraway, 1999) and oral cavity , Muc4/SMC is found only in the most superficial half of the stratified epithelium, the most differentiated cells, and those which are not proliferating. Interestingly, we have also been able to demonstrate complexes of Muc4/SMC and ErbB2 in all of these tissues Idris et al., 2001; Arango and Carraway, unpublished observations) . Since Muc4/SMC is able to enhance p27 kip expression in the A375 cells, we suggest that it may be able to serve as an effector of differentiation in epithelia, rather than just as a product.
A simple model for the putative role of Muc4/SMC as an effector of ErbB signaling is shown in Figure 8 . The key is a switch between the Muc4/SMC -ErbB2 complex and the 'quad complex' of Muc4/SMC - Figure 7 Effect of Muc4/SMC and neuregulin on p27 kip expression. A375 cells with Muc4/SMC ON or OFF were treated with 0 -1 nM neuregulin, as described previously . Cell lysates were immunoblotted with antibodies recognizing p27
kip . Data are representative of three separate experiments (Carraway et al., 2002) . We have shown that Muc4/SMC is apically localized in epithelial cells (McNeer et al., 1998b; Idris and Carraway, 1999; Rossi et al., 1996) and have proposed that it can direct ErbB2 to the apical surface (Carraway et al., 2002) . In contrast, ErbB3 and neuregulin appear to function at basolateral surfaces in such epithelia. Loss of polarization, such as occurs with neoplastic transformation, could induce formation of the 'quad complex', leading to enhanced phosphorylation, increased proliferation and other effects associated with cell transformation. In a normal epithelium this switch might act as a sensor for epithelial damage. In a transformed cell the switch could promote tumor progression. Thus, this mechanism could help to explain some of the schizophrenic aspects of ErbB signaling.
Materials and methods
Analyses of ErbB2 phosphorylation in insect cells
Sf9 insect cell growth, infections, and transfections of ErbB2 and ASGP-2 were carried out as described previously . In co-expression experiments where a single protein was expressed as a control, wild type baculovirus was used as the co-infecting virus. Sf9 cell lysis was performed using RIPA lysis buffer (150 mM NaCl, 1% Nonidet P-40, 0.5% deoxycholic acid, 0.1% sodium dodecyl sulphate (SDS), 50 mM Tris base, pH 8.0). Lysates were cleared by centrifugation at 12 000 g for 15 min prior to immunoprecipitation. Immunoprecipitation of ErbB2 was performed with anti-ErbB2 monoclonal antibody Ab-4 (Calbiochem). Immunoprecipitate was then blotted with anti-phosphotyrosine RC20 (Transduction Laboratories), anti-ErbB2 mAb Ab-3 (Calibiochem), or anti-ASGP-2 mAb 4F12 (Rossi et al., 1996) , and signals were detected using Renaissance TM enhanced chemiluminescence kit (NEN Life Science Products, Boston, MA, USA).
Cell lines and animals
A375 melanoma cells transfected with a tetracycline inducible construct of Muc4/SMC (Rep8) were described previously (Komatsu et al., 1997 (Komatsu et al., , 2000 . These transfectants were maintained in DMEM supplemented with 10% fetal calf serum (FCS), 2 mg/ml tetracycline, 0.5 mg/ml G418 and 0.3 mg/ml Hygromycin. Four-week-old athymic female Ncr (nu/nu) mice were purchased from Taconic (Germantown, NY, USA). The care and use of the animals were in accordance with institutional guidelines. Mice were supplied with either regular drinking water or tetracycline-containing water (1 mg/ml), depending on the purpose of each experiment (Komatsu et al., 2000) .
Immunostaining of tumor sections
Formalin-fixed paraffin-embedded tumor sections were prepared as described previously from A375 melanoma xenografts in nude mice (Komatsu et al., 2000) . Briefly, the Muc4/SMC-transfected A375 cells were grown in tetracycline-containing media. These cells were harvested using trypsin-EDTA, and 5610 5 viable cells in 0.5 ml inoculum volumes were inoculated in the right hand footpad of either tetracycline-fed or animals not given tetracycline (10 animals/ group). When the foot tumor reached 1 cm 2 in size, tumors were resected. Formalin-fixed paraffin-embedded tumor sections (5 mm) were prepared from excised tumors and immunohistochemically stained with anti-ASGP-2 mAb 4F12, anti-ErbB2 Ab-17 (NeoMarkers, Fremont, CA, USA), or anti-phospho-ErbB2 Ab-18 (NeoMarkers). Immunostaining of paraffin sections was performed as described previously . Briefly, the tumor sections were deparaffinized in xylene and hydrated in absolute ethanol followed by successive immersions in a graded series of ethanol-water. Antigenic sites were retrieved from fixed samples using DAKO retrieval solution (DAKO, Carpinteria, CA, USA) for 20 min. Sections were rinsed in PBS, then treated with 3% (v/v) H 2 O 2 to inhibit endogenous In vitro analyses of ErbB2, MAPK and protein kinase B/Akt phosphorylation Muc4/SMC expression was induced in A375 transfectants by removal of tetracycline from the culture as described before (Komatsu et al., 1997) . Muc4/SMC-On cells were collected, seeded onto poly-lysine-coated chamber slides, and further grown overnight in the tetracycline-free media. As a control, Muc4/SMC-repressed (Off) cells were grown on the chamber slide in tetracycline-containing media (2 mg/ml). Cells were fixed with 4% paraformaldehide/PBS solution and rinsed with PBS. Immunofluorescence staining was performed using the same set of antibodies (4F12, Ab-17 and Ab-18) as the primary antibodies and goat anti-mouse or anti-rabbit IgG-FITC conjugate (Sigma) as the secondary antibody. For Western blot analyses, cells were lysed with 0.5% SDS, and the total protein content was determined by a modified Lowry assay (Pierce). Five micrograms total protein was separated on 8% SDS-polyacrylamide gel electrophoresis (PAGE) and blotted with anti-ASGP-2 mAb 4F12, antiErbB2 (DAKO), and anti-phospho-ErbB2 (Up-State Biotechnology) antibodies. Phospho-specific antibodies against Erk1/ 2, p38, JNK, and protein kinase B/akt were all from New England Biolabs.
In vitro analyses of p27 kip expression
Muc4/SMC expression was induced in A375 transfectants by removal of tetracycline from the culture as described before (Komatsu et al., 1997) . Muc4/SMC-On cells were collected, seeded onto polystyrene cell culture dishes or poly-lysinecoated chamber slides, and further grown overnight in the tetracycline-free media. As a control, Muc4/SMC-repressed (Off) cells were grown on the chamber slide in tetracyclinecontaining media (2 mg/ml). Cells were treated with neuregulin for 15 min. Following the treatments, cells were lysed in RIPA buffer plus inhibitor cocktail and prepared for SDS -PAGE on 12% gels, using an equal protein concentration for each sample. Blots were stained with anti-p27 kip (Transduction) followed by second antibody.
